Research ExplorerPublicationsThe Impact of Postoperative Tumor Burden on Patients With Br...

The Impact of Postoperative Tumor Burden on Patients With Brain Metastases

Standard

The Impact of Postoperative Tumor Burden on Patients With Brain Metastases. / Aftahy, Amir Kaywan; Barz, Melanie; Lange, Nicole; Baumgart, Lea; Thunstedt, Cem; Eller, Mario Antonio; Wiestler, Benedikt; Bernhardt, Denise; Combs, Stephanie E; Jost, Philipp J; Delbridge, Claire; Liesche-Starnecker, Friederike; Meyer, Bernhard; Gempt, Jens.

In: FRONT ONCOL, Vol. 12, 2022, p. 869764.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aftahy, AK, Barz, M, Lange, N, Baumgart, L, Thunstedt, C, Eller, MA, Wiestler, B, Bernhardt, D, Combs, SE, Jost, PJ, Delbridge, C, Liesche-Starnecker, F, Meyer, B & Gempt, J 2022, 'The Impact of Postoperative Tumor Burden on Patients With Brain Metastases', FRONT ONCOL, vol. 12, pp. 869764. https://doi.org/10.3389/fonc.2022.869764

APA

Aftahy, A. K., Barz, M., Lange, N., Baumgart, L., Thunstedt, C., Eller, M. A., Wiestler, B., Bernhardt, D., Combs, S. E., Jost, P. J., Delbridge, C., Liesche-Starnecker, F., Meyer, B., & Gempt, J. (2022). The Impact of Postoperative Tumor Burden on Patients With Brain Metastases. FRONT ONCOL, 12, 869764. https://doi.org/10.3389/fonc.2022.869764

Vancouver

Aftahy AK, Barz M, Lange N, Baumgart L, Thunstedt C, Eller MA et al. The Impact of Postoperative Tumor Burden on Patients With Brain Metastases. FRONT ONCOL. 2022;12:869764. https://doi.org/10.3389/fonc.2022.869764

Bibtex

@article{5900aa1668564558b1f17bd21111a821,
title = "The Impact of Postoperative Tumor Burden on Patients With Brain Metastases",
abstract = "BACKGROUND: Brain metastases were considered to be well-defined lesions, but recent research points to infiltrating behavior. Impact of postoperative residual tumor burden (RTB) and extent of resection are still not defined enough.PATIENTS AND METHODS: Adult patients with surgery of brain metastases between April 2007 and January 2020 were analyzed. Early postoperative MRI (<72 h) was used to segment RTB. Survival analysis was performed and cutoff values for RTB were revealed. Separate (subgroup) analyses regarding postoperative radiotherapy, age, and histopathological entities were performed.RESULTS: A total of 704 patients were included. Complete cytoreduction was achieved in 487/704 (69.2%) patients, median preoperative tumor burden was 12.4 cm3 (IQR 5.2-25.8 cm3), median RTB was 0.14 cm3 (IQR 0.0-2.05 cm3), and median postoperative tumor volume of the targeted BM was 0.0 cm3 (IQR 0.0-0.1 cm3). Median overall survival was 6 months (IQR 2-18). In multivariate analysis, preoperative KPSS (HR 0.981982, 95% CI, 0.9761-0.9873, p < 0.001), age (HR 1.012363; 95% CI, 1.0043-1.0205, p = 0.0026), and preoperative (HR 1.004906; 95% CI, 1.0003-1.0095, p = 0.00362) and postoperative tumor burden (HR 1.017983; 95% CI; 1.0058-1.0303, p = 0.0036) were significant. Maximally selected log rank statistics showed a significant cutoff for RTB of 1.78 cm3 (p = 0.0022) for all and 0.28 cm3 (p = 0.0047) for targeted metastasis and cutoff for the age of 67 years (p < 0.001). (Stereotactic) Radiotherapy had a significant impact on survival (p < 0.001).CONCLUSIONS: RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.",
author = "Aftahy, {Amir Kaywan} and Melanie Barz and Nicole Lange and Lea Baumgart and Cem Thunstedt and Eller, {Mario Antonio} and Benedikt Wiestler and Denise Bernhardt and Combs, {Stephanie E} and Jost, {Philipp J} and Claire Delbridge and Friederike Liesche-Starnecker and Bernhard Meyer and Jens Gempt",
note = "Copyright {\textcopyright} 2022 Aftahy, Barz, Lange, Baumgart, Thunstedt, Eller, Wiestler, Bernhardt, Combs, Jost, Delbridge, Liesche-Starnecker, Meyer and Gempt.",
year = "2022",
doi = "10.3389/fonc.2022.869764",
language = "English",
volume = "12",
pages = "869764",
journal = "FRONT ONCOL",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - The Impact of Postoperative Tumor Burden on Patients With Brain Metastases

AU - Aftahy, Amir Kaywan

AU - Barz, Melanie

AU - Lange, Nicole

AU - Baumgart, Lea

AU - Thunstedt, Cem

AU - Eller, Mario Antonio

AU - Wiestler, Benedikt

AU - Bernhardt, Denise

AU - Combs, Stephanie E

AU - Jost, Philipp J

AU - Delbridge, Claire

AU - Liesche-Starnecker, Friederike

AU - Meyer, Bernhard

AU - Gempt, Jens

N1 - Copyright © 2022 Aftahy, Barz, Lange, Baumgart, Thunstedt, Eller, Wiestler, Bernhardt, Combs, Jost, Delbridge, Liesche-Starnecker, Meyer and Gempt.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Brain metastases were considered to be well-defined lesions, but recent research points to infiltrating behavior. Impact of postoperative residual tumor burden (RTB) and extent of resection are still not defined enough.PATIENTS AND METHODS: Adult patients with surgery of brain metastases between April 2007 and January 2020 were analyzed. Early postoperative MRI (<72 h) was used to segment RTB. Survival analysis was performed and cutoff values for RTB were revealed. Separate (subgroup) analyses regarding postoperative radiotherapy, age, and histopathological entities were performed.RESULTS: A total of 704 patients were included. Complete cytoreduction was achieved in 487/704 (69.2%) patients, median preoperative tumor burden was 12.4 cm3 (IQR 5.2-25.8 cm3), median RTB was 0.14 cm3 (IQR 0.0-2.05 cm3), and median postoperative tumor volume of the targeted BM was 0.0 cm3 (IQR 0.0-0.1 cm3). Median overall survival was 6 months (IQR 2-18). In multivariate analysis, preoperative KPSS (HR 0.981982, 95% CI, 0.9761-0.9873, p < 0.001), age (HR 1.012363; 95% CI, 1.0043-1.0205, p = 0.0026), and preoperative (HR 1.004906; 95% CI, 1.0003-1.0095, p = 0.00362) and postoperative tumor burden (HR 1.017983; 95% CI; 1.0058-1.0303, p = 0.0036) were significant. Maximally selected log rank statistics showed a significant cutoff for RTB of 1.78 cm3 (p = 0.0022) for all and 0.28 cm3 (p = 0.0047) for targeted metastasis and cutoff for the age of 67 years (p < 0.001). (Stereotactic) Radiotherapy had a significant impact on survival (p < 0.001).CONCLUSIONS: RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.

AB - BACKGROUND: Brain metastases were considered to be well-defined lesions, but recent research points to infiltrating behavior. Impact of postoperative residual tumor burden (RTB) and extent of resection are still not defined enough.PATIENTS AND METHODS: Adult patients with surgery of brain metastases between April 2007 and January 2020 were analyzed. Early postoperative MRI (<72 h) was used to segment RTB. Survival analysis was performed and cutoff values for RTB were revealed. Separate (subgroup) analyses regarding postoperative radiotherapy, age, and histopathological entities were performed.RESULTS: A total of 704 patients were included. Complete cytoreduction was achieved in 487/704 (69.2%) patients, median preoperative tumor burden was 12.4 cm3 (IQR 5.2-25.8 cm3), median RTB was 0.14 cm3 (IQR 0.0-2.05 cm3), and median postoperative tumor volume of the targeted BM was 0.0 cm3 (IQR 0.0-0.1 cm3). Median overall survival was 6 months (IQR 2-18). In multivariate analysis, preoperative KPSS (HR 0.981982, 95% CI, 0.9761-0.9873, p < 0.001), age (HR 1.012363; 95% CI, 1.0043-1.0205, p = 0.0026), and preoperative (HR 1.004906; 95% CI, 1.0003-1.0095, p = 0.00362) and postoperative tumor burden (HR 1.017983; 95% CI; 1.0058-1.0303, p = 0.0036) were significant. Maximally selected log rank statistics showed a significant cutoff for RTB of 1.78 cm3 (p = 0.0022) for all and 0.28 cm3 (p = 0.0047) for targeted metastasis and cutoff for the age of 67 years (p < 0.001). (Stereotactic) Radiotherapy had a significant impact on survival (p < 0.001).CONCLUSIONS: RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.

U2 - 10.3389/fonc.2022.869764

DO - 10.3389/fonc.2022.869764

M3 - SCORING: Journal article

C2 - 35600394

VL - 12

SP - 869764

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

ER -